Tracers / [68Ga]DOTA-A1-His
[68Ga]DOTA-A1-His
Also written as [Ga-68]Ga-DOTA-A1-His
- Radionuclide
- Ga-68 t½ 67.71 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical
- Syntheses indexed
- 1
What it is
- Compound class
- DOTA-conjugated anti-mesothelin single-domain antibody (nanobody)
- Target / mechanism
- Mesothelin-targeting single-domain antibody (sdAb) PMID 40833585
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | — | 96 ± 2% | p-SCN-Bn-DOTA-A1-His | 40833585 2025 EJNMMI Radiopharm Chem 100 µg of DOTA- or NOTA-conjugated A1-His (7 nmoles) in 1 M ammonium acetate were added to Ga-68 eluate (145–222 MBq). |
Need this precursor?We can point you to suppliers for [68Ga]DOTA-A1-His, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40833585. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40833585: 'p-SCN-Bn-DOTA-A1-His'. Stage set/updated at stage 23 from PMID 40833585: 'Biodistribution and imaging studies in mice bearing mesothelin-expressing tumors showed specific tumor targeting for both tracers.'.